Cogent Biosciences, Inc. (COGT) FY2025 10-K Annual Report
Cogent Biosciences, Inc. (COGT) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 17, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Cogent Biosciences, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: Clinical-stage biotech developing precision therapies targeting genetically defined diseases, focusing mainly on tyrosine kinase inhibitors like bezuclastinib
- • New emphasis: Positive top-line Phase 2/3 results in 2025 for bezuclastinib in Non-Advanced/Advanced Systemic Mastocytosis and GIST; expecting U.S. launches in H2 2026
Management Discussion & Analysis
- • Net loss $328.9M in 2025 vs $255.9M in 2024, increase of $73M; no product revenue generated
- • R&D expense $269.8M in 2025 vs $232.7M in 2024, up $37.1M; G&A $63.6M vs $43.3M, up $20.3M
Risk Factors
- • Regulatory risk: FDA NDA submissions for bezuclastinib in NonAdvSM (2025) and GIST (expected April 2026) may face approval delays or rejections
- • Macroeconomic threat: U.S. healthcare pricing pressure from May 2025 White House Most Favored Nation drug pricing policy impacting reimbursement
Cogent Biosciences, Inc. FY2025 Key Financial MetricsXBRL
Net Income
-$329M
▼ -28.6% YoY
ROE
-51.7%
▲ +4814bp YoY
Total Assets
$938M
▲ +185.9% YoY
EPS (Diluted)
$-2.16
▼ -11.3% YoY
Operating Cash Flow
-$264M
▼ -27.3% YoY
Source: XBRL data from Cogent Biosciences, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Cogent Biosciences, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.